| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514140900 | Thrombosis affecting | 17 |
| 20100267638 | EXOSITE-DIRECTED THROMBIN INHIBITORS - Disclosed are an amino acid sequence of the human blood clotting factor Va, peptides containing such sequence, and additional peptides of interest that significantly inhibit thrombin generation. Also disclosed are pharmaceutical compositions containing these peptides and related therapeutic methods for inhibiting thrombin generation and treating blood coagulation disorders. | 10-21-2010 |
| 20110009326 | METHODS OR USE OF LAMIN B1 NUCLEAR ANTIGEN, FRAGMENTS AND COMPOSITIONS THEREOF, FOR INHIBITING OR REDUCING A THROMBOTIC EVENT - A method for preventing a thrombotic event in a patient susceptible to such an event, which comprises the step of administering an effective amount of a lamin 131 nuclear (LB1) antigen to said patient is provided along with an anti-thrombotic composition which comprises an effective amount of a lamin 131 nuclear (LB1) antigen and a pharmaceutically acceptable carrier. | 01-13-2011 |
| 20110059895 | MODULATION OF FACTOR 9 EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing Factor 9 and increasing clotting time in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 9 include thrombosis, embolism, thromoboembolism such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. | 03-10-2011 |
| 20110082083 | FORMULATIONS OF LIQUID STABLE ANTITHROMBIN - In one aspect, the invention provides liquid stable formulations of antithrombin. | 04-07-2011 |
| 20110207669 | RECOMBINANT PROTEINS HAVING HAEMOSTATIC ACTIVITY AND CAPABLE OF INDUCING PLATELET AGGREGATION - Disclosed herein are recombinant proteins capable of inducing platelet aggregation and uses thereof. | 08-25-2011 |
| 20110306552 | PYRIMIDINONE INHIBITORS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 - The present invention relates to new pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof | 12-15-2011 |
| 20120196806 | ANTICOAGULANT AND COMPOSITION FOR PREVENTING THROMBUS CONTAINING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to an anticoagulant and a composition for preventing thrombus formation, which contain poly-gamma-glutamic acid (PGA) as an active ingredient. The inventive PGA is a water-soluble, anionic, biodegradable and edible amino acid polymer material, which has an anticoagulant effect of preventing thrombi from being accumulated in blood vessels, shows an excellent sustained-release effect and is harmless to the human body. Thus, it is useful as a high-value-added anticoagulant and a food or beverage composition for preventing thrombus formation. | 08-02-2012 |
| 20120232014 | ANTITHROMBOTIC COMPOUNDS - A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane binding element via a joining element, wherein the joining element between the anticoagulant and the membrane binding element is less than about 10,000 daltons in weight. These compounds can be used in therapy and, in particular, in preventing or reducing blood coagulation. As a result, a method of treatment is provided comprising administering an effective amount of the compounds to a subject to prevent or reduce blood coagulation as well as a method of perfusing an organ, tissue or cell comprising contacting the compounds with the organ, tissue or cell to prevent or reduce blood coagulation. Also disclosed is an organ, tissue or cell which has been perfused with the compounds. | 09-13-2012 |
| 20130035289 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF THROMBOSIS-RELATED DISEASES COMPRISING A FRAGMENT OF PROLACTIN (PRL)-GROWTH HORMONE (GH)-PLACENTAL LACTOGEN (PL)-FAMILY PROTEIN - The present disclosure relates to a pharmaceutical composition for use in the preventive and/or therapeutic treatment of thrombosis-related diseases or conditions relating to high level of plasminogen activator inhibitor 1 (PAI-1) expression, which composition comprises: A) a fragment of a polypeptide or protein of prolactin (PRL)-growth hormone (GH)-placental lactogen (PL)-family and homologous derivatives thereof, which fragment comprises from 6 to 14 consecutive amino acid residues of the amino acid sequence having general formula (I); or B) a peptide or a recombinant protein comprising said peptide, wherein the peptide is from 6 to 50 amino acids in length and has the activity to inhibit PAI-1, said peptide comprising from 6 to 14 consecutive amino acid residues of the amino acid sequence of general formula (I); or C) a polynucleotide encoding said fragment of a polypeptide or protein of A) or said peptide or recombinant protein of B). | 02-07-2013 |
| 20130274195 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 10-17-2013 |
| 20140051634 | PHARMACEUTICAL COMBINED PREPARATION CONTAINING A THERAPEUTIC PROTEIN - A pharmaceutical combined preparation containing a therapeutic protein having SH-groups which are nitrosated and a compound containing thiol groups and having an average molecular weight of at most 10,000. | 02-20-2014 |
| 20140162955 | Antagonizing Heparin With Salicylamide Compounds And Histamine Blocking Agents - The present disclosure provides combinations of salicylamide compounds, or pharmaceutically acceptable salts thereof, and histamine blocking agents, or pharmaceutically acceptable salts thereof, for antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative. | 06-12-2014 |
| 20140221291 | Compositions and Methods for Modulating Thrombin Generation - Factor V peptides and methods of use thereof are disclosed. | 08-07-2014 |
| 20140364368 | STIMULUS RESPONSIVE NANOCOMPLEXES AND METHODS OF USE THEREOF - The present invention provides stimulus responsive nanocomplexes comprising a masking moiety, e.g., a peptide, and a therapeutic moiety, e.g., an anti-coagulant. The invention also provides methods for treating or preventing a condition, such as a hypercoagulable state, e.g., blood clotting disorders or a cardiovascular disease, in a subject. | 12-11-2014 |
| 20140364369 | USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE - The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. | 12-11-2014 |
| 20150105322 | Non-N-Glycosylated Recombinant Human Annexin A2 - Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in | 04-16-2015 |
| 20160060293 | COMPOSITIONS AND METHOD FOR TREATING THROMBOSIS - A peptide, derivative or peptidomimetic the blocks binding of GNA12 to αSNAP is provided as are methods of using the same to inhibit thrombin-induced von Willebrand Factor secretion and prevent or treat thrombosis. | 03-03-2016 |
